Concepedia

Marc Chioda

MC

Statistics

Publications

16

Citations

623

H-Index

14

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

Matrix Research (United States)

Triangle

McKesson (United States)

Marc Chioda is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, oncology, and medicine.

Publications per year

2007–2025

16

Publications

16

Clinical Management of Adverse Events Associated with Lorlatinib

Todd M. Bauer, Enriqueta Felip, Benjamin Solomon et al. · The Oncologist · 2019 · 162 citations · Full text

, , +17

Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

Harry R. Chobanian, Yan Guo, Ping Liu et al. · ACS Medicinal Chemistry Letters · 2012 · 62 citations · Full text

, , +12

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners

Mollie Lehner Reed, Aimee-Lauren S. Rosales, Marc Chioda et al. · Advances in Therapy · 2020 · 54 citations · Full text

, , +15

Discovery of Benzodiazepine Sulfonamide-Based Bombesin Receptor Subtype 3 Agonists and Their Unusual Chirality

Ping Liu, Thomas J. Lanza, Marc Chioda et al. · ACS Medicinal Chemistry Letters · 2011 · 45 citations · Full text

, , +11

Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain

Harry R. Chobanian, Yan Guo, Ping Liu et al. · ACS Medicinal Chemistry Letters · 2014 · 41 citations · Full text

, , +15

1–5 of 16